Vaccine allocation in a declining epidemic

Journal of the Royal Society Interface

Volumn 9, Issue 76, 2012, Pages 2798-2803

  Goldstein, E ^a   Wallinga, J ^b   Lipsitch, M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

High risk; Influenza pandemic; Mortality; Vaccination

Indexed keywords

EPIDEMIOLOGY; HEALTH RISKS; POPULATION STATISTICS; VACCINES;

HEALTH CONDITION; INFLUENZA PANDEMICS; MORTALITY; PANDEMIC INFLUENZA; PRIORITIZATION; RISK FACTORS; SEASONALITY; VACCINATION;

RISK PERCEPTION;

INFLUENZA VACCINE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVELOPMENTAL DISORDER; EPIDEMIC; GROUPS BY AGE; HEALTH CARE MANAGEMENT; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; KIDNEY DISEASE; MORBID OBESITY; MORTALITY; NEUROLOGIC DISEASE; PANDEMIC INFLUENZA; PRIORITIZATION; RESOURCE ALLOCATION; RISK ASSESSMENT; SEASONAL VARIATION; VACCINATION;

EID: 84867468109     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2012.0404     Document Type: Article

References (34)

1. Fowlkes, A. L. et al. 2011 Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin. Infect. Dis. 52(Suppl. 1) S60-S68. (doi:10.1093/cid/ciq022)
2. Louie, J. K. et al. 2009 Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. J. Am. Med. Assoc. 302, 1896-1902. (doi:10.1001/jama.2009.1583)
3. Flu.Gov. 2010 U.S. sees increase in H1N1 flu activity, 29 March. See http://www.flu.gov/news/blogs/increasedactivity.html.
4. Pleis, J. R., Lucas, J. W. & Ward, B. W. 2009 Summary health statistics for U.S. adults: National health interview survey, 2008. Vital Health Stat. 10, 1-157.
5. Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R. & Zalutsky, R. 2007 How common are the 'common' neurologic disorders? Neurology 68, 326-337. (doi:10.1212/01.wnl.0000252807.38124.a3)
6. Zimmerman, R. K., Lauderdale, D. S., Tan, S. M. &Wagener, D. K. 2010 Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine 28, 6470-6477. (doi:10.1016/j.vaccine.2010.07.037)
7. Flegal, K. M., Carroll, M. D., Ogden, C. L. & Curtin, L. R. 2010 Prevalence and trends in obesity among US adults, 1999-2008. J. Am. Med. Assoc. 303, 235-241. (doi:10.1001/jama.2009.2014)
8. Wallinga, J., van Boven, M. & Lipsitch, M. 2010 Optimizing infectious disease interventions during an emerging epidemic. Proc. Natl Acad. Sci. USA 107, 923-928. (doi:10.1073/pnas.0908491107)
9. Mylius, S. D., Hagenaars, T. J., Lugner, A. K. & Wallinga, J. 2008 Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26, 3742-3749. (doi:10.1016/j.vaccine.2008.04.043)
10. Matrajt Jr, L. & Longini, I. M. 2010 Optimizing vaccine allocation at different points in time during an epidemic. PLoS ONE 5, e13767. (doi:10.1371/ journal.pone.0013767)
11. Shaman, J., Pitzer, V. E., Viboud, C., Grenfell, B. T. &Lipsitch, M. 2010 Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biol. 8, e1000316. (doi:10.1371/journal.pbio.1000316)
12. US Centers for Disease Control and Prevention. 2009 ACIP vaccination recommendations for the 2009 H1N1 influenza epidemic. See http://www.cdc.gov/ media/pressrel/2009/r090729b.htm.
13. US Centers for Disease Control and Prevention. FluView, US CDC Influenza Division. See http://www.cdc.gov/flu/weekly/.
14. US Centers for Disease Control and Prevention. United States surveillance data. See http://www.cdc.gov/flu/weekly/ussurvdata.htm.
15. Donnelly, C. A. et al. 2011 Serial intervals and the temporal distribution of secondary infections within households of 2009 pandemic influenza A (H1N1): implications for influenza control recommendations. Clin. Infect. Dis. 52(Suppl. 1), S123-S130. (doi:10.1093/cid/ciq028)
16. Cauchemez, S., Donnelly, C. A., Reed, C., Ghani, A. C., Fraser, C., Kent, C. K., Finelli, L. & Ferguson, N. M. 2009 Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N. Engl. J. Med. 361, 2619-2627. (doi:10.1056/NEJMoa0905498)
17. Yang, Y., Sugimoto, J. D., Halloran, M. E., Basta, N. E., Chao, D. L., Matrajt, L., Potter, G., Kenah, E. & Longini, I. M. 2009 The transmissibility and control of pandemic influenza A (H1N1) virus. Science 326, 729-733. (doi:10.1126/science.1177373)
18. Cowling, B. J., Fang, V. J., Riley, S., Malik Peiris, J. S. &Leung, G. M. 2009 Estimation of the serial interval of influenza. Epidemiology 20, 344-347. (doi:10.1097/EDE.0b013e31819d1092)
19. Goldstein, E., Cobey, S., Takahashi, S., Miller, J. &Lipsitch, M. 2011 Predicting the epidemic sizes of influenza A/H1N1, A/H3N2 and B: a statistical method. PLoS Med. 8, e1001051. (doi:10.1371/journal.pmed.1001051)
20. US Centers for Disease Control and Prevention. United States census estimates. See http://wonder.cdc.gov/bridged-race-population.html.
21. Massachusetts Department of Public Health. 2009 Recommendations for the use of influenza A (H1N1) 2009 monovalent vaccine. See http://www.neias.org/pdf/ MA09VInactH1N1OrdersRev112309.pdf.
22. Connecticut Department of Public Health. H1N1 vaccine distribution response plan. See http://www.ct.gov/ctfluwatch/lib/ctfluwatch/h1n1/h1n1- vaccine-dist-plan-809.pdf.
23. Chang, Y. T., Guo, C. Y., Tsai, M. S., Cheng, Y. Y., Lin, M. T., Chen, C. H., Shen, D., Wang, J. R. & Sung, J. M. 2012 Poor immune response to a standard single dose non-adjuvenated vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine 30, 5009-5018. (doi:10.1016/j.vaccine.2012.05.016)
24. Andrews, N., Waight, P., Yung, C. F. & Miller, E. 2011 Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 203, 32-39. (doi:10.1093/infdis/jiq014)
25. Emborg, H. D., Krause, T. G., Hviid, A., Simonsen, J. &Molbak, K. 2012 Effectiveness of vaccine against pandemic influenza A/ H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. Br. Med. J. 344, d7901. (doi:10.1136/bmj.d7901)
26. Simpson, C. R., Ritchie, L. D., Robertson, C., Sheikh, A. &McMenamin, J. 2010 Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol. Assess. 14, 313-346.
27. Simonsen, L., Taylor, R. J., Viboud, C., Miller, M. A. & Jackson, L. A. 2007 Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis. 7, 658-666. (doi:10.1016/S1473-3099(07) 70236-0)
28. UK Health Protection Agency. Swine flu vaccination: what you need to know. See http://www.direct.gov.uk/prod-consum-dg/groups/dg-digitalassets/@dg/ @en/documents/digitalasset/dg-181508.pdf.
29. Kettler, B. 2009 Focus of H1N1 vaccination effort shifts. Mail Tribune, 14 November 2009. See http://www.mailtribune.com/apps/pbcs.dll/article?AID=/ 20091114/NEWS/911140310.
30. Zimmer, S. et al. 2010 Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE 5, e11601. (doi:10.1371/journal.pone.0011601)
31. Wu, J. T. et al. 2011 Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med. 8, e1001103. (doi:10.1371/journal.pmed. 1001103)
32. Goldstein, E., Cowling, B. J., Aiello, A. E., Takahashi, S., King, G., Lu, Y., Lipsitch, M. & Yates, A. 2011 Estimating incidence curves of several infections using symptom surveillance data. PLoS ONE 6, e23380. (doi:10.1371/journal.pone.0023380)
33. Lipsitch, M., Finelli, L., Heffernan, R. T., Leung, G. M. &Redd, S. C. 2011 Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. Biosecur. Bioterror. 9, 89-115.
34. Shaman, J., Goldstein, E. & Lipsitch, M. 2011 Absolute humidity and pandemic versus epidemic influenza. Am. J. Epidemiol. 173, 127-135. (doi:10.1093/aje/kwq347)